Advanced Code injection

OBIO News

Rostrum, Southlake and OBIO® team up to evaluate a non-invasive, real time, bedside monitoring system to manage mechanically ventilated patients in the ICU

January 31, 2024 (Vancouver, B.C.) – Over 350,000 patients in Canada are admitted into the intensive care unit (ICU) annually, with 40% of those patients needing invasive mechanical ventilation. Managing mechanically ventilated patients can be complex due to providers having to simultaneously treat the underlying condition and the potential impacts a ventilator may have on the patient, which can lead to costly complications. The most common ventilator related complications or injuries are to a patient’s heart or lungs. In fact, up to 50% of mechanically ventilated patients experience complications, contributing in part to the ICU’s usage of 20 percent of hospital resources.

Currently, there is no real time, single solution to evaluate the impact on a patient’s cardio-pulmonary health from mechanical ventilation. Current methods are often invasive and time consuming, require extensive training and only provide partial information by focusing on one organ and ignoring the impacts of any intervention on the other.

Through OBIO’s Early Adopter Health Network (EAHN™), Rostrum Medical Innovations, a British Columbia-based medical device start-up, secured a partnership with Southlake Regional Health Centre to evaluate Pulmonary Blood Flow (PBF) when measured by their novel VQm® System as compared to the reference standard in the ICU.

Rostrum Medical Innovation’s VQm® System is a bedside cardio-pulmonary health monitoring system that addresses the gap in clinical monitoring solutions of the heart and lungs for invasively mechanically ventilated patients in the ICU. The VQm® System consists of a standalone monitor, a proprietary sensor and a per patient that connects the monitor to any standard ventilator breathing circuit. Rostrum’s VQm® System also measures dead space, shunt fraction and functional residual capacity, giving providers the information they need to streamline ICU clinical workflows and reduce costs for mechanically ventilated patients.

This evaluation which is the product’s first clinical application in an ICU setting has demonstrated VQm® System’s ability to detect changes in PBF. Compared to the reference standard, the VQm® System showed a concordance of 83% to the standard of care. The VQm® System can also assess the impact of intravenous (IV) fluid on a patient’s heart and lung function allowing point of care adjustments which may reduce the rate of complications. Current ICU methods to generate the same type of data would cost upwards of $43,000 per patient per day, whereas the VQm® System can provide it daily for approximately $250 per patient for the duration of ICU care. Ultimately this solution has the potential to empower the healthcare team by giving them non-invasive, bedside access to valuable clinical measurements.

“We are very grateful to have worked with an amazing team from Southlake and we are proud with what the results are showing,” said Nathan Ayoubi, COO, Rostrum Medical Innovation. “We are committed to continuing our efforts to bring the VQm® System into other sites across the country.”

“The ability of this technology to generate physiological measurements non-invasively and in a semi-continuous manner could prove highly valuable within the ICU setting,” said Dr. Bryn Fell, Critical Care Medicine and Internal Medicine Specialist, Southlake Regional Health Centre. “We need to study this device in the ICU to see if any single or a combination of its four outputs could be used to tailor patient care, whether that be through more effective oxygenation and ventilation titration, fluid and pressor optimization, or another outcome. More study is needed, but preliminary results are promising.”

“We are pleased to provide an opportunity to a B.C.-based company to access the Ontario healthcare market and in turn potentially improve cost efficiencies in our healthcare system,” said Dr. Maura Campbell, President and CEO, OBIO®. “The success of this project truly exemplifies the pan-Canadian nature of EAHN™, which has partnered with companies and healthcare organizations in five provinces.”

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit OBIO.ca.

About Rostrum Medical Innovations

Rostrum Medical Innovations is dedicated to empowering medical practitioners with new and useful solutions to help solve everyday challenges that medical professionals face. Rostrum was established with a goal to deliver novel solutions to problematic uncertainties in modern day practice. With a team of some of the world’s most progressive clinicians, combined with engineering and business expertise with a history of commercial success, Rostrum is driven by one mission – to address clinical needs in healthcare. For more information, please visit www.rostrummedical.com.

About Southlake Regional Health Centre

Southlake is building healthy communities through outstanding care, innovative partnerships, and amazing people. We deliver a wide range of healthcare services to the communities of northern York Region and southern Simcoe County. Our advanced regional programs include Cancer Care and Cardiac Care and serve a broader population across the northern GTA and into Simcoe-Muskoka.

Our team of 6,000 staff, physicians, volunteers, students and Patient and Family Advisors are committed to creating an environment where the best experiences happen. As a recognition of our commitment to quality and patient safety, we have received the highest distinction of Exemplary Standing from Accreditation Canada.

With an annual operating budget of over $550 million, we are for one of Ontario’s most rapidly growing and aging populations and have developed an exciting plan for new facilities to serve our communities into the future. A member of the Southlake Community Ontario Health Team, we are working with our partners to deliver connected care to northern York Region and southern Simcoe County. For more information, please visit southlake.ca.

Media Contacts:

For more information, please contact:

Bibaswan Ghoshal
Senior Director, Technology Adoption
Ontario Bioscience Innovation Organization (OBIO®)

Nathan Ayoubi
Chief Operating Officer
Rostrum Medical Innovation

Lindsey Furlanic
Communications Strategist, Corporate Communications
Southlake Regional Health Centre

The Ottawa Hospital is the first in the world to use Vena Medical’s breakthrough stroke technology

The physicians at The Ottawa Hospital (TOH) were the first in the world to use new stroke technology, the Vena MicroAngioscope™, in a patient procedure. Equipped with the world’s smallest camera, the device goes inside veins and arteries, allowing physicians to see inside the blood vessels of the patient’s brain. The use of the MicroAngioscope™ marks a significant development in the field of neurovascular care and will pave the way for new, innovative treatments for patients across the region. 

Vena Medical is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™ and H2BB™ programs and presented at the OBIO® Investment Summit.

Virica expands bioprocessing capabilities with Carleton University partnership

Virica Biotech Inc., a leading developer of cell enhancers for scaling of viral vectors and cell and gene therapies, is expanding bioprocessing services through a strategic partnership with Carleton University. Slated to open this spring, Virica’s new facility at the university multiplies the company’s capacity to provide high throughput virology services for customers looking to optimize production of their cell and gene therapies.

Virica Biotech is an OBIO® member, an alumnus of our BDSP™ program and recipient of the WiHI Leadership subsidy.

Swift Medical secures new financing round to further enhance its AI-based wound care technology

Swift Medical, a digital health technology company serving wound care providers, recently announced the successful closing of an $US8M round of financing co-led by current investors BDC Capital’s Women in Technology Venture Fund and funds managed by Virgo Investment Group. Swift utilizes artificial intelligence to improve clinical and economic outcomes in chronic and acute wound care, and this financing will accelerate its pace of technology enhancements.

Swift Medical is an OBIO® member and an alumnus of our BDSP™ and CAAP® programs.

Eurofins CDMO Alphora announces the completion of a new pilot scale biologics development facility

Eurofins CDMO Alphora Inc., a contract drug and manufacturing organization based in Mississauga, recently announced the successful completion of its pilot-scale biologics development facility. Spanning 3,300 square feet, the facility is dedicated to the development and scaling of monoclonal antibodies (mAbs) and other mammalian-based therapeutic proteins.

We are pleased to count Eurofins CDMO Alphora as an OBIO® member, and also as a sponsor of the OBIO® Investment Summit happening this month.

Cohesys awarded $1.62M from MTEC to support BoneTape, a revolutionary fracture fixation technology

Cohesys, an innovative medical device company focused on novel solutions for fracture treatment, has been selected for a $1.62M award by the Medical Technology Enterprise Consortium (MTEC) in collaboration with the Department of Defense (DoD) U.S. Army Medical Research and Development Command (USAMRDC). This award will advance development and clinical validation for BoneTape, a revolutionary resorbable bone fixation device designed to improve fracture treatment.

Cohesys is an OBIO® member and an alumnus of our BDSP™, CAAP® and H2BB™ programs.

AI-Driven Clinical Trial Pre-Screening by K2 Medical Research, Magruder Eye Institute and RetiSpec

K2 Medical Research, a leading clinical research organization committed to advancing medical science, has partnered with the renowned Magruder Eye Institute and Toronto-based medical AI company, RetiSpec, to redefine Alzheimer’s research through AI-driven technology. The partnership aims to leverage advanced artificial intelligence (AI) technology as a pre-screening tool for clinical trials, with the objective of enhancing trial accessibility and reducing the time associated with recruitment of eligible candidates. The collaboration aims to utilize RetiSpec’s AI technology as a pre-screening tool at Magruder Eye Institute.

Retispec is an OBIO® member, an alumnus of the BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.

FluidAI Medical announces a $25M manufacturing investment in Ontario

FluidAI Medical has developed an AI-powered monitor that detects post-operative gastrointestinal leaks, preventing complications that can arise from their late detection. The company’s investment will be used to research product improvements, build an automated assembly line to meet growing international demand and will create 38 jobs. In support of FluidAI’s investment, Ontario is providing over $1.4M in funding through the Advanced Manufacturing and Innovation Competitiveness stream of the Regional Development Program.

FluidAI Medical is an OBIO® member, an alumnus of BDSP™, CAAP®,EAHN™, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.

KA Imaging’s Premium Dual-Energy Mobile System now available for sale in the U.S.

FluidAI Medical has developed an AI-powered monitor that detects post-operative gastrointestinal leaks, preventing complications that can arise from their late detection. The company’s investment will be used to research product improvements and build an automated assembly line to meet growing international demand and will create 38 jobs. In support of FluidAI’s investment, Ontario is providing over $1.4 million in funding through the Advanced Manufacturing and Innovation Competitiveness stream of the Regional Development Program.

KA Imaging is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™, H2BB™, HealthMINT™ and presented at the OBIO® Investment Summit.

OBIO® Celebrates the Advancement of Women in Health Science with WiHI Seed Program and Leadership Awards

January 4, 2024 (Toronto, ON) – The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce significant milestones for its Women in Health Initiative (WiHI). Launched in July 2022 with support from the Government of Canada, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), the OBIO® WiHI aims to bridge the gender disparity in the health science industry, particularly in senior management roles and leadership positions. The program offers comprehensive training, support and networking opportunities, empowering women with the skills and knowledge required to excel in leadership positions.

“Investing in the Women in Health Initiative (WiHI) is a crucial step in providing necessary supports and training so women can enter and flourish in the health and life sciences sector,” said the Honourable Filomena Tassi, Minister responsible for FedDev Ontario. “Southern Ontario is home to an abundance of healthcare-focused businesses—many more of which are women-led thanks to the committed efforts of WiHI. Our government is pleased to support the WiHI program as it works to increase the representation of women in this exciting field.”

In its first year, WiHI has made remarkable strides, supporting more than 325 women in the industry through experiential learning and financial support. This year, 11 women-led companies have been selected for the WiHI Seed Program, a key component of the initiative, which addresses the significant barriers that women-led companies face in accessing financing and support, especially in the health science sector where venture capital investment is at a historic low. The participating companies will benefit from this comprehensive six-month program and have access to expert networks, essential industry resources and skills, non-dilutive funding of up to $20,000 and potential equity investment.

“By providing a combination of early-stage capital and advisory support to women-led companies, the program addresses critical barriers faced by women entrepreneurs in the life science and health technology sectors,” said Dr. Maura Campbell, President & CEO of OBIO®. “The WiHI Seed Program is a critical step towards creating a more equitable, diverse and inclusive health science industry, empowering women entrepreneurs to thrive and be successful leaders.”

The selected companies for the WiHI Seed Program 2023 are A.I. VALI, Atorvia, Cove Neurosciences, HDAX Therapeutics, ImaginAble Solutions, mDETECT, MoxyPatch, Noa Therapeutics, Paradox Immunotherapeutics, Tenomix, and Vessl Prosthetics. These companies will receive comprehensive support, including non-dilutive funding, tailored advisory and coaching assistance, and opportunities to pitch for equity seed investment.

Other exciting WiHI highlights

We are delighted to welcome Monika Yazdanian (CEO and Co-founder of ToeFX Inc.) and Mai Elfarnawany (VP Engineering at Flosonics Medical) as recipients of the Women in Health Initiative Business Leadership Program, joining our previous eight awardees. The program celebrates women that are exemplary leaders, role models and mentors to other women in the industry. The awardees (who each receive a $50K wage subsidy) will participate in OBIO’s networking events and contribute as mentor leaders to a women’s professional development community to support workforce development in a sector where women are underrepresented.

“As a recipient of the WiHI Seed and Women in Health Initiative Business Leadership programs, I am deeply grateful for the opportunities and support OBIO® has provided to us. It is encouraging to see a focused effort to challenge systemic biases and create a level-playing field for women entrepreneurs,” said Natalie Galant, CEO of Paradox Immunotherapeutics. “The WiHI Seed Program symbolizes a transformative shift, empowering women entrepreneurs to excel and innovate. It's about creating a more inclusive future in health science, and I'm proud to be part of this change."

We are also excited to share that OBIO® WiHI has received the first ever honourable mention ACE (Advancement, Commitment, Engagement) award from the Healthcare Businesswomen’s Association (known as HBA), a global not-for-profit organization dedicated to furthering the advancement and impact of women in the business of healthcare. Represented in countries across the globe, the HBA serves a community of more than 75,000 individuals and 180 corporate partners. 

The ACE award recognizes results-oriented initiatives fostered by organizations committed to ensuring that gender equity and leadership opportunities for women are part of their organizational DNA. A panel of healthcare leaders selects recipients for their excellence in advancing their female talent and removing the systemic barriers preventing timely progress to parity. Award criteria include measurable results, business performance, stewardship, execution, and sustainability. Read more.

Furthermore, WiHI was nominated for the Women Leaders in Pharma Awards for The Women Support Network award. This award recognizes companies that have supported the women’s network through networking, coaching, and mentoring.

About OBIO®

Founded in 2009, OBIO® is a not-for-profit membership-based innovation organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies that position Canada as a leader in the international marketplace. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the health care system and government. For more information, please visit obio.ca and follow OBIO® on LinkedIn and Twitter.

About FedDev Ontario
For 14 years, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada’s most populous region. The Agency has delivered impressive results, which can be seen in southern Ontario businesses that are creating innovative technologies, improving productivity, growing revenues, creating jobs, and in the economic advancement of communities across the region. Learn more about the impacts the Agency is having in southern Ontario by exploring our pivotal projects, our Southern Ontario Spotlight, and FedDev Ontario’s Twitter, Facebook, Instagram and LinkedIn.

Media Contacts:

Doriane Rey
Manager, Marketing & Events
Ontario Bioscience Innovation Organization (OBIO®)
dorianerey@obio.ca

Edward Hutchinson
Press Secretary
Office of the Minister responsible for the Federal Economic Development Agency for Southern Ontario
edward.hutchinson@feddevontario.gc.ca

XPAN secures FDA 510(k) clearance and announces successful completion of initial human clinical cases in the U.S.

Xpan Inc., a medical device company focused on minimally invasive surgical innovation, secured FDA 510(k) clearance on the XpanTM Universal Trocar System – a device that can be tailored by surgeons during laparoscopic procedure, reducing complications and improving quality of care for patients.

XPAN is an OBIO® member, an alumnus of our BDSP™, CAAP®, H2BB™ and HealthMINT™ programs and presented at the OBIO® Investment Summit.

Seeing patients from the inside out: Realize Medical featured on national CTV News

Realize Medical, an Ottawa-based virtual reality start-up, was featured on CTV News, showing how its virtual reality (VR) innovation, Elucis, enables surgeons to plan surgical procedures and improve patient treatment. Elucis lets you easily segment images into 3D models, collaborate with multiple remote colleagues and plan procedures all within virtual reality.

Realize Medical is a CAAP® company and presented at the 2021 OBIO® Investment Summit. They will be presenting at the 2024 OBIO® Investment Summit next month along with other exciting companies.

OBIO® affiliated companies among selected funded projects to accelerate digital health innovations

The Ontario Centre of Innovation (OCI) announced the funding of projects through the Innovating Digital Health Solutions Program (IDHS), an initiative, funded by the Ontario government, aimed at fast-tracking digital health innovations in Ontario. IDHS, delivered by the Ontario Centre of Ontario (OCI), will invest $8.2 million across 13 approved projects designed to revolutionize healthcare delivery across the province.

We are thrilled to share that four of the selected companies, Health Espresso, Hypercare, OPTT and Swift Medical, are OBIO® affiliated companies.

Phyxable Partners with Right at Home and OBIO® to Revolutionize Senior Healthcare with Falls Prevention Program

December 19, 2023 (Markham, ON) – Each year in Canada, up to one third of seniors are at risk of falling due to physiological factors associated with aging. Once a fall has occurred, there is very limited traditional, in-person rehabilitation programs for seniors with reduced mobility, and especially for those living in rural areas. To address this issue, OBIO® has partnered with Phyxable and Right at Home Canada in a collaborative effort to provide equitable access to effective falls prevention. Through OBIO’s Early Adopter Health Network (EAHN™), Phyxable and Right at Home Canada have revolutionized falls prevention rehabilitation with AgeWell, a digitally guided exercise program.

"Following a successful evaluation of AgeWell, Phyxable is thrilled to see the positive impact our digitally guided falls prevention exercise program has had on the lives of community-dwelling Canadian seniors. The collaboration with Right at Home Canada and the support from OBIO® has allowed us to address a critical need for accessible and effective falls prevention rehabilitation. The results of the study demonstrate not only significant improvements in strength and balance, but also a high level of satisfaction among participants,” said Dr. Jim Feng, CEO of Phyxable. “We are committed to continuing our mission of transforming healthcare and empowering individuals to take charge of their well-being from the comfort of their homes. We extend our sincere gratitude to OBIO® for their unwavering commitment to supporting the commercialization of Ontario-made biosciences companies like Phyxable."

The AgeWell program, delivered through the Phyxable app, combines live video-based care sessions with licensed healthcare providers and self-paced exercises. Accessible from any internet-connected device, the exercises cater to individual preferences, enabling seniors to enhance their lower extremity strength and balance.

“It was a great experience collaborating with Phyxable and creating the Fall Prevention Program. Our community clients thoroughly enjoyed the support and expertise from our collaboration with Phyxable and OBIO® ,” said Sharlene Hogeterp Louden, Registered Kinesiologist at Right at Home Canada. “The feedback from the users was very positive and they all improved their knowledge of fall prevention - to be proactive instead of reactive.”

“Phyxable partnered with Right at Home Canada to address the high incidence of falls among community-dwelling seniors. We created an engaging and dynamic falls prevention program which included twenty-five sessions of progressive strength and balance exercises, as well as six live virtual coaching calls with registered healthcare providers. Clients successfully adopted this digitally guided program and reported a high level of satisfaction with the hybrid model of virtual coaching and in-home assistance from Right at Home Canada caregivers,” said Anna Michalski, Registered Physiotherapist. “We were able to objectively measure balance, leg power, and fear of falling at the start and end of the program and are very excited to report improvements across all metrics. We hope the Falls Prevention Program empowers seniors to improve their mobility and allows them to maintain a high level of independence in their homes.”

This EAHN™ evaluation study revealed positive changes in key health measures in participants following the program:

  • The 30-second chair stand test showed an improvement of approximately 11.52%

  • Handgrip strength increased by about 7.24%

  • The Falls Efficacy Scale-International (FES-I) score decreased by roughly 4.85%

  • Average balance scores increased by around 1.40%

Participants gave a high rating of 9/10, indicating the effectiveness of the program and their satisfaction with it.

Furthermore, feedback from app users indicated a high level of satisfaction with the app:  

  • Users found the Phyxable app easy to follow (89%),

  • Users rated the quality of the video as good or very good (89%)

  • Users were satisfied with the length of the sessions (84%)

Most importantly, all app users felt comfortable with the virtual coaching calls, valued the presence of a caregiver to set up the program and would recommend the program to others.

The data from this study strongly supports the effectiveness of the falls prevention exercise program in improving strength, balance and reducing the perception of falls risk among community-dwelling Canadian seniors. The high satisfaction levels and positive outcomes indicate the successful adoption of this innovative approach, marking a significant stride in advancing senior community-based healthcare and well-being.

“OBIO® is proud to be partnered with Phyxable and Right at Home Canada to address the issue of falls prevention for seniors in the community,” said Dr. Maura Campbell, President and CEO of OBIO®. “The results of the AgeWell app’s evaluation reflect the profound impact that simple, easy-to-use technology can have on the lives of seniors. We are eager to continue supporting Phyxable in the next steps of procurement and wider adoption of their product across Canada’s healthcare systems.”

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace.

For more information, please visit OBIO.ca or contact Bibaswan Ghoshal, Senior Director, Technology Adoption, OBIO®.

About Phyxable

Phyxable is a pioneering virtual rehabilitation platform committed to transforming the healthcare landscape. Born and bred in Markham, Ontario, Phyxable combines telemedicine, machine vision, and video content to redefine how physical pain and injury are managed and prevented. Our mission is to empower individuals to receive high-quality care from the comfort of their homes, ensuring accessibility and convenience for all. With virtual 1-on-1 video calls, asynchronous chat systems, self-help exercise prescriptions, and augmented reality motion detection, Phyxable is at the forefront of innovative healthcare solutions.

For more information, please visit Phyxable's website or contact Jeannie Allen, Patient Success Advisor, Phyxable.

About Right at Home Canada

Right at Home is one of the largest providers of in-home supportive care services, staffing and employer solutions, globally. With over 600 Care Offices in 8 countries around the world, and 55 offices in Canada, they are a trusted resource for tens of thousands of families, clients, residential living organizations, employers and government agencies in the delivery of a wide variety of highly personalized, quality suppor

For more information, please visit Right at Home's website or contact Rica Esguerra, National Director of Community Engagement, Right at Home Canada

OBIO® launches national health science technology training program powered by Upskill Canada

December 7, 2023 (Toronto, ON) – The Ontario Bioscience Innovation Organization (OBIO®) has launched its national Health Science Technology Training for Software and Data Professionals training program, powered by Upskill Canada. The program is part of the first wave of partnership agreements that are taking an industry-oriented approach to supporting Canadian workers. These agreements will help thousands of workers find new careers through skills training and job placement in some of the most dynamic industries in Canada.

The program will support fast-growing health science employers developing digital technologies to address their talent needs, create new career paths for individuals who want to transition into high-demand roles in health science and attract tech professionals with the necessary expertise to fill these roles.

Up to 100 participants will be upskilled through the program to help them secure their next role in the industry by integrating foundational software skills with industry-specific knowledge. Over 14 weeks, the program will cover topics including software development for health science, regulatory frameworks for software as a medical device, data compliance, cybersecurity, AI & machine learning, and foundational skills.

Supported by funding from Innovation, Science and Economic Development Canada’s (ISED) Upskilling for Industry Initiative, more than 15,000 Canadian workers will benefit from an innovative approach to skills training. Central to the Upskill Canada initiative is the role of community training providers, who work closely with local and national employers to identify precise suites of skills being sought by industry. Equipping workers with these skills will create new career pathways for Canadians and better position Canadian companies to compete both domestically and internationally.

Quick Facts

  • OBIO® supports early-stage and venture backed companies enabling them to raise capital, build the workforce, and accelerate commercialization and adoption.

  • OBIO’s Workforce Development programs support in-demand skills development of the life science workforce to remove barriers faced by employers in the labour market, enabling access to industry-ready talent, and facilitating hiring and retention.

  • Individuals interested in applying for the first cohort of the Health Science Technology Training for Software and Data Professional as talent participants can complete and submit an application by December 15 at: obio.ca/health-science-technology-training.

Quotes

“We’re so proud to formally launch Upskill Canada with our inaugural class of workers and training service providers. This is a big first step – but it’s only the beginning. We’re looking forward to working with our supporters in government and industry to upskill many more Canadians, so they can transition into high-demand roles in the modern workforce – and help fast-growing companies achieve their full potential.”

– Rhonda Barnet, CEO of Palette Skills, which was chosen by ISED to run the Upskill Canada initiative

“OBIO® is thrilled to partner with Upskill Canada to deliver the national Health Science Technology Training for Software and Data Professionals training program. Developing the health technology workforce and enabling talent to transition into high-demand technology roles will enable Canadian companies to commercialize and adopt digital technologies faster, giving them a competitive edge on a global scale.”

– Dr. Maura Campbell, President and CEO of OBIO®

To learn more, visit paletteskills.org/upskillcanadaprograms.

About OBIO®

Founded in 2009, OBIO® is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies that position Canada as a leader in the international marketplace. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the healthcare system and government. For more information, please visit obio.ca and follow OBIO® on LinkedIn and X (formerly Twitter).

About Upskill Canada

Upskill Canada is a national talent platform that helps fast-growing companies access the talent they need to compete and succeed globally while creating new career pathways for workers to rapidly transition into high-demand roles. Upskill Canada will target all regions of the country and support Canadian-based employers, with a particular focus on small to medium-sized enterprises (SMEs). It will focus on strengthening key growth sectors, including digital technology, cybersecurity, agricultural technology, advanced manufacturing, clean technology and biomanufacturing.

Media contact:

Doriane Rey
Manager, Marketing & Events
dorianerey@obio.ca  

Microbix Clot-Buster Drug Fully-Funded for Return to U.S. Market

Microbix Biosystems Inc., a life sciences innovator, manufacturer and exporter, recently announced the reconfirmation of its agreement with Sequel Pharma, LLC to return Kinlytic® urokinase to market in the United States, followed by other geographies and clinical indications. Kinlytic is an enzyme derived from human cell cultures that dissolves the material of a blood clot. A further payment of US$ 2.0 million has been received by Microbix relating to this reconfirmation.

Microbix is an OBIO® member and an alumnus of the BDSP™ and H2BB™ programs.

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care

AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round. The proceeds will be used to accelerate the clinical development of the AMT-143 formulation, with the objective of it being a best-in-class, non-opioid, therapeutic able to provide an extended period of post-surgical pain relief and reduce with the aim of eliminating the need for opioids in the postsurgical recovery period. 

AmacaThera is an OBIO® member, an alumnus of all OBIO® programs and presented at the OBIO® Investment Summit.

Phenomic AI Enters Strategic Collaborations with Boehringer Ingelheim & Astellas

Phenomic AI recently announced a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic’s expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers.


Phenomic AI has recently entered a strategic research collaboration with Astellas for solid tumor cell therapies. For this collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of the tumor stroma identified with Phenomic’s scTx platform, to enhance cell therapy approaches for the treatment of solid tumors.

Phenomic AI is an alumnus of OBIO's HealthMINT™ program and presented at the OBIO® Investment Summit.

New technology aims to improve access to cancer care

November 28, 2023 (Toronto, ON) – The Ottawa Hospital (TOH), the Ontario Bioscience Innovation Organization (OBIO®), and Gray Oncology Solutions (Gray) are thrilled to announce the results of the deployment and evaluation of a new technology developed in Canada and aimed at optimizing operations in cancer care.

Over the past few decades, remarkable strides in cancer treatment have significantly improved the treatment of patients. While offering exciting possibilities, these advances have also introduced a high level of complexity that can be a challenge to manage effectively.

The scheduling of care journeys, which plays a pivotal role in ensuring patients’ access to care and the optimal use of hospital resources, is a highly manual and inefficient process, leading to increased administrative burden, wait times and cost of care delivery.

In a concerted effort to maintain the quality of care and maximize hospital resources, TOH partnered with Gray to deploy and evaluate their novel technology, GrayOS. This project was carried out with support from OBIO’s Early Adopter Health Network (EAHN™).

GrayOS is the operating system for cancer care, which automates and optimizes the operations of cancer centres. It was co-developed with the Centre hospitalier de l’Université de Montréal (CHUM) and now deployed in clinics across multiple provinces, where it has been proven to increase efficiencies, reduce administrative overhead, save costs and improve staff experience.

TOH, one of Canada’s largest learning and research hospitals, became the first Ontario hospital to introduce and evaluate the technology. TOH, Gray and OBIO® are excited to share the preliminary results of this evaluation.

In less than six months, the solution saved costs and reduced the administrative burden by 60%. After GrayOS was deployed, TOH reported a 17% increase in the rate of patients treated within the targeted time outlined by Cancer Care Ontario, which is the provincial agency that sets standards for cancer care.

“Using GrayOS has played a pivotal role in reducing our operational challenges in radiation oncology,” said Melissa Diffey, Manager, Radiation Medicine Program at The Ottawa Hospital. “With this innovative technology, we are now able to further streamline our workflow and improve wait times by scheduling more patients within the targeted treatment deadline.”

The team will continue to monitor the results as further impact is expected from the efficiency gain.

“We’re incredibly grateful that The Ottawa Hospital has been such a great partner in deploying, testing and evaluating our technology. The meaningful results and interest we’ve received from Québec and now Ontario signal that we are on the right track to addressing a significant challenge in cancer care,” added André Diamant, CEO of Gray.

“OBIO® is proud to have partnered with The Ottawa Hospital and Gray Oncology Solutions on this inter-provincial project. The results of this evaluation reflect the impact of using cutting-edge technology in healthcare to improve clinical efficiency and enhance patient care. We are eager to continue to support GrayOS in the next steps of procurement and wider adoption across Ontario’s healthcare systems,” said Dr. Maura Campbell, President and CEO of OBIO®.

GrayOS will continue to help The Ottawa Hospital treat more patients with the same amount of resources by unlocking additional capacity to prioritize scheduling in a way that minimize gaps in the calendar.

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace.

For more information, please visit OBIO.ca or contact Bibaswan Ghoshal, Senior Director, Market acceleration at bibaswanghoshal@obio.ca.

About Gray Oncology Solutions

Gray Oncology Solutions (Montréal-based start-up) has a vision of a healthcare ecosystem with no resources wasted. In pursuit of this vision, they have developed an “operating system” which simplifies cancer treatment by streamlining workflows across multiple points of cancer care (GrayOS). Operationally, this translates to the optimization & automation of patient scheduling while explicitly incorporating the complex multi-disciplinary workflow resulting in increased access to care, reduced patient wait times, increased patient/staff satisfaction and ultimately superior patient care.

For more information, please visit www.gray-os.com or contact André Diamant, CEO at andre@gray-os.com.

About The Ottawa Hospital

The Ottawa Hospital (TOH) is one of Canada’s top learning and research hospitals where we are guided by our vision to provide the world-class and compassionate care we would all want for our loved ones. Our multi-campus hospital, affiliated with the University of Ottawa, is home to the Regional Trauma Centre and Cancer Centre, and to discoveries that are adopted globally.

Backed by generous support from the community, we are focused on reshaping the future of health care to improve the health of our diverse population of patients from Eastern Ontario, Western Quebec, and Nunavut.

For more information about The Ottawa Hospital, please visit OttawaHospital.on.ca or contact Alison Jennings, Manager (acting) Digital Innovation at ajennings@toh.ca.

QurCan to participate in Novo Nordisk's program

QurCan Therapeutics has been selected to participate in Novo Nordisk's Co-Creation Greenhouse Program. Anchored through the Novo Nordisk Bio Innovation Hub, this collaboration provides QurCan with funding and deep scientific and technical expertise in translational and drug development.

QurCan Therapeutics is an OBIO® member, an alumnus of the BDSP™, CAAP® and HealthMINT™ programs and presented at the OBIO® Investment Summit.